Author Manuscript Published OnlineFirst on November 27, 2017; DOI: 10.1158/0008-5472.CAN-17-1653 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging Hailey E. Brighton1,2,+; Steven P. Angus3,+; Tao Bo1; Jose Roques1; Alicia C. Tagliatela1,2; David B. Darr1; Kubra Karagoz4, Noah Sciaky3, Michael L. Gatza4 Norman E. Sharpless1,5,6; Gary L. Johnson1,3; James E. Bear*1,2,3 + equal contribution 1UNC Lineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, NC, USA 2Department of Cell Biology and Physiology, UNC Chapel Hill, Chapel Hill, NC, USA 3Department of Pharmacology, UNC Chapel Hill, Chapel Hill, NC, USA 4Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA 5Department of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA 6Department of Genetics, UNC Chapel Hill, Chapel Hill, NC, USA *Corresponding Author: James E. Bear UNC Lineberger Comprehensive Cancer Center CB 7295 Chapel Hill, NC 27599 Phone: 919-966-5471
[email protected] Running Title: Intravital Imaging of Melanoma Growth and Response to MAPKi Abbreviations List: GEM: genetically engineered mouse, CL: collagen, ECM: extracellular matrix, SHG: second harmonic generation, 4-HT: 4-Hydroxytamoxifen, PBT: Tyr::CreER; BRAFCA;PTENlox/lox GEM model, wpa: weeks post-application, dpa: days post-application, MT: masson’s trichrome, TRAMETINIB&E: Hematoxylin and Eosin staining, RTK: receptor tyrosine kinase, CI: confidence interval, MIB/MS: multiplexed-inhibitor bead affinity chromatography coupled with mass spectrometry, EMT: epithelial to mesenchymal transition, M-E-T: mesenchymal to epithelial transition, WB: western blotting, IHC: immunohistochemistry Financial Support: This work was supported by HHMI funds to J.E.